Radiotherapy with or without temozolomide in elderly patients aged ≥ 70 years with glioblastoma
Introduction : Although the recommended optimal treatment of glioblastoma multiforme (GBM) is adjuvant chemoradiotherapy, trials in GBM have excluded patients older than 70 years. In this study, we aimed to assess overall survival (OS) and prognostic factors in elderly patients (≥ 70 years) with new...
Main Authors: | Evrim Metcalfe, Ozden Karaoglanoglu, Emine Akyazici |
---|---|
Format: | Article |
Language: | English |
Published: |
Termedia Publishing House
2016-08-01
|
Series: | Contemporary Oncology |
Subjects: | |
Online Access: | https://www.termedia.pl/Radiotherapy-with-or-without-temozolomide-in-elderly-patients-aged-70-years-with-glioblastoma,3,28094,1,1.html |
Similar Items
-
Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years
by: Makoto Ohno, et al.
Published: (2019-11-01) -
Radiotherapy plus temozolomide in elderly patients with glioblastoma: a “real-life” report
by: J. Biau, et al.
Published: (2017-12-01) -
Effect of temozolomide on survival in elderly patients with glioblastoma and impaired performance status: a propensity score–matching analysis
by: Liu Y, et al.
Published: (2017-08-01) -
Treatment options and outcomes for glioblastoma in the elderly patient
by: Arvold ND, et al.
Published: (2014-02-01) -
Glioblastoma in Elderly Patients: Current Management and Future Perspectives
by: Giuseppe Minniti, et al.
Published: (2019-03-01)